September 11th, 2012 by InvestorPoint
September 7th, 2012 by InvestorPoint
September 5th, 2012 by InvestorPoint
August 30th, 2012 by InvestorPoint
August 30th, 2012 by InvestorPoint
August 24th, 2012 by InvestorPoint
August 22nd, 2012 by InvestorPoint
August 22nd, 2012 by InvestorPoint
…continued
…continued
vaccine pharmaceutical vaccines …continued
genetic pharma stemenhance
August 14th, 2012 by InvestorPoint
August 14th, 2012 by InvestorPoint
…continued
frx pharmaceuticals pharmaceutical …continued
…continued
August 10th, 2012 by InvestorPoint
August 10th, 2012 by InvestorPoint
…continued
biotechnology falta pharmaceutical …continued
pharmaceuticals empresas biologics
August 9th, 2012 by InvestorPoint
August 9th, 2012 by InvestorPoint
…continued
Drugs biotechnology pharmaceutical …continued
…continued
Services
August 9th, 2012 by InvestorPoint
August 9th, 2012 by InvestorPoint
August 7th, 2012 by InvestorPoint
…continued
coverage Technology phone …continued
stratagene cart pharmaceutical
June 25th, 2012 by InvestorPoint
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that its stock has been added the Russell 3000® Index. The final list of 2012 additions was posted June 22 nd on www.russell.com. Derma Sciences stock has been included in the Russell Microcap® Index since 2010. Annual reconstitution of Russell’s U.S. indexes captures the 3,000 largest U.S. stocks as of the end of May, ranking them by total market capit…continued
DSCI derma wound pharmaceutical
June 21st, 2012 by InvestorPoint
While Moody’s revised ratings are better than its initial guidance of up to three notches, we believe the ratings still do not fully reflect the key strategic actions we have taken in recent years. However, their acknowledgment of our long-term partnership with MUFG as well as our industry-leading capital and liquidity highlight some of the transformative steps we have taken. With our de-risked balance sheet, stable sources of funding, diverse business mix and strong leadership team, we are wel…continued
MS pharmaceutical inflation Dealers
June 20th, 2012 by InvestorPoint
FORT LEE, N.J., June 20, 2012 /PRNewswire/ – Herborium Group, Inc., (HBRM) www.herborium.com, a Botanical Therapeutics® Company announces today that it has begun manufacturing its new sexual health product line for women and men. Herborium proprietary products will launch in the Fall of 2012 in coordination with a promotion of a unique Kamasutra vodka product with natural herbs provided by Herborium and developed based on a know-how associated with the co…continued
HBRM pharmaceutical pharmaceuticals naturopathic
June 20th, 2012 by InvestorPoint
Latest Discovery Studio® release accelerates molecular simulations for life sciences BRUSSELS, June 20, 2012 /PRNewswire/ – Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced the release of Accelrys Discovery Studio ® 3.5 modeling and simulation software during the company’s European Science Symposium in Brussels. The latest release extends Discovery Studio’s portfolio of small-molecule ligand design and market-leadi…continued
ACCL dashboards pharmaceutical Technology
June 19th, 2012 by InvestorPoint
SAN DIEGO, June 19, 2012 /PRNewswire/ — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Specialised Therapeutics Australia Pty, Ltd. (STA) announced today the execution of an exclusive agreement to register and commercialize fidaxomicin tablets in Australia and New Zealand for the treatment of Clostridium difficile Infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) “CDI presents a serious bacterial health threat and current CDI treatment options are limited. …continued
OPTR Drugs Healthcare pharmaceutical
June 19th, 2012 by InvestorPoint
PARSIPPANY, N.J., June 19, 2012 /PRNewswire/ – PDI, Inc. (Nasdaq: PDII), today announced that it is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, 2012 according to a preliminary list of additions posted June 8, 2012 on www.russell.com. Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capital…continued
PDII Services pharmaceutical commercialization
June 15th, 2012 by InvestorPoint
NEW YORK, June 15, 2012 /PRNewswire/ — Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 12-Civ-4711, on behalf of all persons who purchased AEterna Zentaris Inc. (“AEterna” or the “Company”) (NASDAQ GM: AEZS) securities between February 3, 2010 and April 1, 2012 inclusive (the “Class Period”). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO) If you wish to obtain…continued
AEZS biotechnology pharmaceutical biotech